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ABSTRACT
Objectives: Vaccinations protect children against deadly diseases and approximately 30
immunizations are recommended for children by 6 years of age. However, immunization
injections cause negative short- and long-term consequences for children. The Gate Control
Theory of Pain suggests that physical interventions (e.g., rubbing the site) may be helpful, but
they are not well validated for children’s acute pain. This randomized trial examined the
effectiveness of the ShotBlocker®, a physical intervention designed to decrease children’s
injection pain.

Methods: Participants included 89 4- to 12-year-old children receiving immunizations at a
pediatric practice. Participants were randomized to ShotBlocker®, placebo control, or typical
care control groups. Measures of child distress included self-report, parent report, healthcare
provider report, change in heart rate, and observational behavioral coding.

Results: No group differences were evident on any of the measures of child pain or anxiety when
controlling for child age, nor were there any significant interactions of treatment condition with
child age. On the observational distress measure, ANCOVAs revealed significantly higher
distress in the injection than pre- or post-injection phases, and post-injection distress was higher
than pre-injection phase distress, irrespective of treatment condition.

Discussion: The data do not support the effectiveness of the ShotBlocker® for acute pediatric
pain relief. Clinical and theoretical implications are discussed.
KEY WORDS:
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A Randomized Controlled Trial of the ShotBlocker® for Children’s Immunization Distress
INTRODUCTION
Childhood immunizations are a priority for the pediatric patient and the general public;
however, pain resulting from these needle injection results in short- and long-term negative
repercussions for the child. The immediate impact is high levels of fear, anxiety, and pain during
the medical visit; and long-term outcomes include potential elevated distress during upcoming
procedures and avoidance of future healthcare.1
To counter these issues, pain management has included pharmacological (e.g., topical
anesthetics), behavioral (e.g., distraction), and physical approaches (e.g., massage). Whereas
pharmacological and behavioral treatments have received significant attention, physical
approaches have received less attention.1 Physical interventions, involving direct stimulation of
the area near the noxious stimulus, include massage, touching, rubbing, acupuncture, and
transcutaneous electrical nerve stimulation (TENS).2
The Gate Control Theory of pain3 offers a theoretical explanation of how physical
interventions might reduce pain. The theory suggests that pain is transmitted from the peripheral
nervous system to the central nervous system where it is modulated by a gating system in the
dorsal horn of the spinal cord. Physical stimulation – such as rubbing, massage, and vibration –
activates the fast, large diameter, myelinated nerve fibers (A-beta) and inhibits the transmission
(closes the gate) of pain, which travels via the small diameter unmyelinated fibers (A-delta).
One novel and inexpensive physical intervention is the ShotBlocker® (Manufactured by
Bionix®; Toldeo, Ohio), a small, flat u-shaped plastic device, measuring approximately 70mm
by 50mm across at its widest points and 2mm thick, with rounded nubs to stimulate the skin
around the site of the injection (see Figure 1). The device potentially provides more consistent

stimulation than techniques such as pressing, pinching, or stretching. Theoretically, the
stimulation by the pressing down of the nubs on the skin should send fast A-beta signals to the
brain and interfere with the slow A-delta pain transmission of the injection, consistent with the
Gate Control Theory of pain.3
Although conceptually sound, there are few data in support of the manufacturer’s claim
that the ShotBlocker® “blocks the pain of minor injections without the use of chemical
refrigerant sprays or drug based creams.”4 To date, there are four studies available that have
evaluated the ShotBlocker®. Two of these studies, found on the Bionix® website, support the
efficacy of the ShotBlocker®.5,6 The unpublished study by Gundrum et al. is available only in a
brief abstract form. The study enrolled 99 patients over the age of five years (specific ages were
not presented), who were randomized to receive immunizations with or without the
ShotBlocker®. The authors reported significantly reduced pain in the intervention group;
however, specific details of method (e.g., randomization, procedure), statistics, or results were
not provided. It appears that child self-report of pain was the exclusive dependent variable. An
unpublished study conducted by Guevarra, also presented only in abstract form, included 119
pre-kindergarten students in the Philippines who were receiving intramuscular injections.
Participants in the treatment group reported significantly lower pain scores on the Wong-Baker
Faces Pain Rating Scale.7 Similar to the previous study, no measure of behavioral pain or
observer report was examined, no placebo group was included, and additional information about
methodology is limited.
The remaining two studies do not provide evidence that the ShotBlocker® is an effective
intervention to reduce children’s immunization pain. Drago et al.8 evaluated the device with 165
2-month- to 17-year-old participants. Parents and nurses rated participants’ pain on a 6-point

likert scale and children over 36 months of age provided self-report using the Wong-Baker Faces
Pain Rating Scale. 7 Parents and nurses rated children’s pain lower when using the
ShotBlocker®; however, there were no significant group differences in children’s self-reported
pain. Unfortunately, this study was only presented as a conference poster and additional details
about design and procedure (e.g., randomization) are not available. The fourth study, printed in a
nursing research newsletter9, detailed a two-group, randomized, controlled research study that
included a diverse sample of 171 children between the ages of 3 months and 17 years. Parents
and children old enough to provide self-reported pain ratings rated children’s pain using the
Faces Pain Scale-Revised (FPS-R).10 There were no significant differences in pain ratings
between the experimental and control group.9 Given the paucity and mixed results available and
that no data have appeared in a peer-reviewed publication, a more thorough evaluation of the
ShotBlocker’s® effectiveness is in order.
Summary and Purpose
In summary, immunization injections cause multiple negative short- and long-term
consequences for children. The Shotblocker® is an inexpensive and easy-to-use device that
might mitigate children’s injection pain. Theoretically, the device should stimulate nerve
receptors that interfere with pain processing. The purpose of the current study was to provide a
thorough evaluation the Shotblocker®. Based on theoretical underpinnings and the results of the
two abstracts,5,6 it was hypothesized that the ShotBlocker® would result in significantly lower
pain scores on child self-report, parent-report, nurse-report, behavioral observation, and
physiological measures in comparison to both typical care control and placebo control. A
secondary expected finding was that placebo would provide small, but statistically significant,
reductions in pain.

MATERIALS AND METHODS
Participants
Participants included 89 parent-child dyads presenting for pediatric immunization
injections at a southeastern pediatric practice in the Metro-Atlanta area between March, 2006 and
July, 2006. The children ranged from 4 to 12 years of age (M = 8.46 years, SD = 2.97 years).
Children younger than the age of 4 were not included, because they would not likely be able to
provide valid self-report ratings of pain. Children up to 12 years of age were included to increase
external validity in applying findings to school-aged children. Using the effects size of 1.18
found in a prior study of the ShotBlocker®,5 a power analysis with power of .87 revealed that
only 12 participants would be needed to detect differences using a 3-group analysis of variance
(ANOVA). However, given the prior mixed findings, a more conservative sample of 30
participants per condition was deemed sufficient to find treatment effects. Inclusion criteria
included any 4- to 12-year-old English speaking child receiving inoculations at the clinic.
Fifty-two of the child participants were male (58.2%) and 76 were White (85.4%). Five
children were African American (5.6%), one child was Asian American (1.1%), and seven
children were reported as “mixed” or “other” by their parents (7.8%). Children primarily came
from two-parent homes with 79 parents (88.8%) indicating they were married. Seven parents
(7.8%) indicated they were separated or divorced and two parents (2.2%) reported that they were
single. All children enrolled in the study were accompanied by either their mother (75, 84.3%) or
father (14, 15.7%). Parents ranged in age from 28 to 59 years of age (M = 40.2 years, SD = 5.7
years); however, three parents chose not to report their date of birth. The parents’ years of
education ranged from 12 to 23 years (M = 15.78 years, SD = 1.74 years). The majority of
families (78, 60.3%) reported annual income of $90,000 or greater.

Approximately half of the sample (50.5%) received only one injection, 17 children
(18.3%) received two injections, 14 children received three injections (15.1%), and nine children
received four injections (10.3%). Researchers did not record the type of immunization or
whether the injections were subcutaneous or intramuscular.
Measures
Background information
Parents who agreed to participate in the study completed a questionnaire assessing
demographics of both the child and parent in order to provide descriptive information about the
sample so that external validity might be assessed and to evaluate whether variables potentially
influencing pain experiences and perceptions were equally distributed across the three conditions
(i.e., whether randomization was successful). The child’s gender, age, race, and family income
were included as part of the demographics questionnaire. The parent also answered questions
regarding any medical conditions that would require regular injections; any pain-reducing
medications the child may have received prior to the procedure (e.g., acetaminophen); and if,
when, and how the child was informed of receiving an injection. In addition, the parents were
queried as to whether or not the child was born premature, and if so whether the child received
neonatal intensive care.
Child distress
Children rated their pain both pre- and post-injection using the using the Faces Pain Scale
– Revised (FPS-R),10 which is a modified version of the original Faces Pain Scale11 and contains
six cartoon faces expressing no pain to extreme pain and scored from 0-10. The faces are
presented to the child, who is told, “These faces show how much pain a child can feel. This face
(point to face) shows no pain. The faces show more and more pain up until this one (point to

face). It shows very much pain.” The child is then asked to select a face that represents either
their current level of pain or level of pain during the injection. This measure was designed to
create minimal cognitive demands on the child, thus making it appropriate for children of young
ages. Research has shown that this measure has adequate reliability and validity.10 However,
because the sample included children as young as 4 years old, children who rated their preinjection level of pain as a 4 or higher were not included in post-injection pain ratings, given that
they likely did not understand the measure or were possibly reporting high level of anxiety in
addition to physical pain. Ten child post-injection ratings were excluded for this reason.
In addition to the children’s indication of their pain, parents rated their children’s
injection pain and anxiety using Visual Analog Scale (VASs). These measures consisted of 100
mm horizontal lines with anchor descriptors at either end of the continuum (e.g., “no pain” and
“severe pain”). Parents were asked to draw a vertical mark on the continuum to rate their child’s
pain in response to the question, “How much pain did your child experience during the
injection?” and anxiety in response to the question, “How much anxiety did your child
experience during the injection?” This measure has been shown to be valid and reliable for both
children and adults and is commonly used in pain research.12 After the injection, the health-care
provider also rated the pain and anxiety of the children using similar VAS’s.
Children’s distress was also assessed via heart rate. Research has supported the use of
heart rate as a physiological measure of pain, showing decreased heart rate when analgesics were
administered and decreased heart rate as a result of behavioral interventions13. In addition, heart
rate is recommended because of its ease of use and non-invasive nature.13 That said, it should be
noted that heart rate is reactive to emotional state, movement, room temperature, and other
factors besides pain. 13,14 A small electronic monitor, the Tanita® Cardio (Tanita® Corporation

of America, Inc., Arlington Heights, IL) was used to take an electronic reading of the children’s
heart rate at baseline and then immediately following the injection. The precision is ±5% for
pulses between 30-200 beats per minute. Each child’s change in heart rate from baseline to post
injection served as the physiological measure of distress.
Finally, children’s distress was coded using three relevant behavioral indicants of
distress. The behaviors were consistent with those used and validated in other behavioral scales
(e.g., Child-Adult Medical Procedure Interaction Scale;15 the Observational Scale of Behavioral
Distress16). The behaviors were: crying, screaming, and adult restraint. Initially, coders were
trained to code using videotape data from a prior study. Once interrater agreement had been
achieved (i.e., Cohen’s Kappa of .80), coding of study data commenced. Coders remained blind
to study hypotheses and spanned from three minutes prior to the nurse prepping the injection site
by wiping it with alcohol until three more minutes after the final needle was removed. In order to
examine differences across phases of the procedure, a total observational distress composite
(combining all 3 behavioral codes) was calculated, as well as behavioral scores for pre-injection
(3 minutes before until cleaning of the site), injection (cleaning of the site until the needle was
removed), and post-injection (removal of the needle until 3 minutes later). The behaviors were
coded for occurrence in five-second intervals. Ratio of distress behavior was calculated by
dividing the number of intervals of distress by the total number of intervals. Interrater reliability
for coding in the current study was 93.6% agreement for crying, 98.4% agreement for screaming,
and 95.2% agreement for adult restraint of the child.
Procedure
The study procedure and its informed consent form were approved by the Georgia State
University Institutional Review Board. This study was designed in accord with, and adheres to

the guidelines detailed in the Consolidated Standards of Reporting Trials (CONSORT)
statement17,18,19 (see Figure 2 for the CONSORT Flowchart). Eligible participants were typically
approached in the exam room between checking in with the nurse and visiting with the
pediatrician. Research assistants described the study to parents and obtained parent consent and
child assent from those interested in participating. The informed consent explained the
randomization process for group assignment. Parents and children were told that random
assignment, similar to drawing straws, was done by computer ahead of time. In two of the groups
a small plastic device would be put on the child’s arm and the third group would the typical care
usually administered by the staff. They were also informed that of the two ShotBlocker® groups,
one was a placebo group and they would not know until the end of the study which group they
were assigned.
With the help of the research assistant, the parent completed the demographics
questionnaire. The research assistant also measured the baseline heart rate of both the parent and
child. Participants were randomly assigned to either the typical care control (Typical Care
Control), the placebo control (Placebo Control), or the ShotBlocker® condition. The
randomization was determined prior to the study via a random number table generated by the
RanSL computer program.20 Once participants completed all pre-injection measures, the research
assistant opened an envelope, which contained the participant condition assignment. Consistent
with the explanation provided in the consent form, the parent(s) and child were only told if they
were in the typical care group or one of the two ShotBlocker® groups.
After the family had finished visiting with the pediatrician, the researcher re-entered the
exam room and set up the video camera, which was used to collect data for observational coding.
Before leaving the room, the research assistant began recording, with the video camera focused

on the exam table where injections were administered. The research assistant privately informed
the nurse of the assigned condition so that the nurse was aware of the proper group protocol to
follow.
ShotBlocker®
Participants in the ShotBlocker® condition received the intervention according to protocol. The
nurse used the following script to introduce and describe the ShotBlocker®:
“(Nurse shows child device). This is called the ShotBlocker. It is used to help
make shots hurt less. I am going to hold it against your arm like this (nurse
demonstrates on own arm) while I give you your shot. It doesn’t hurt at all.
Would you like to hold it and see what it feels like? Now I will show you how it
feels on your arm.” (Nurse demonstrates on child’s arm. If child is in the
ShotBlocker® group, press the device with nubs against skin. If child is in
Placebo control, press the device with smooth side against the skin.)
Once the nurse was prepared to administer the injection, she/he pressed the
ShotBlocker® firmly against the child’s skin at the injection site with the raised nubs in direct
contact with the child’s skin. The device was placed on the child’s arm for no more than 20
seconds prior to the injection and held in place until the injection was complete.
Placebo control
Participants assigned to the placebo control group received the same scripted introduction
to the medical device that was used with the ShotBlocker® condition participants. They were not
aware that they were assigned to the placebo control group. The health care provider placed the
ShotBlocker® on the child’s arm with the smooth side against the child’s skin, opposite as
prescribed. This prevented the small rounded nubs from contacting the child’s skin. The purpose

of this condition was to test for any placebo effect (e.g., child or parent expectancy the device
might have in reducing the child’s experienced pain and anxiety).
Typical care control
The typical care control group received treatment as usual and the health care provider
was asked to administer the intramuscular injection without the use of the ShotBlocker®. No
other instructions or guidance about pain management were provided to the health care provider.
In all three conditions and immediately following the injection, the health care provider
obtained child heart rate. The research assistant re-entered the exam room after the procedure to
turn off the video camera and assist the parent and child with post-injections forms After all
forms were completed, children and parents who participated in the Placebo group were
debriefed and told that they were part of the placebo control group, and then the research
assistant demonstrated the correct use of the ShotBlocker® device with the nubby side against
the skin. Participants in the placebo control and ShotBlocker® groups were allowed to keep their
ShotBlocker® to use for future injections. All children received a small toy (e.g., small bouncing
ball, pencil) to thank them for their participation. The research assistant then administered the
post-injection VAS to the nurse.
RESULTS
In order to ensure that randomization resulted in equivalent groups, an ANOVA was used
to compare the three conditions (Typical Care Control, Placebo, and ShotBlocker®) on child age
and number of injections received and revealed no significant group differences (Table 1). Chisquare analyses indicated no differences between groups on child gender; race; history of NICU
hospitalization; or existing medical condition that requires extra blood draws, injections, or IVs
(Table 1). Thus, random assignment successfully balanced potentially relevant factors across the

three groups.
The next set of preliminary analyses examined bivariate correlations among demographic
variables, specifically age, gender, and ethnicity, to determine whether considerations (e.g.
covariates or interactions) of these variables would be needed in subsequent analyses. Results
revealed inverse correlations between child’s age and all ratings of child pain and anxiety (e.g.,
child-, caregiver-, and nurse-report) and observational coding of child distress (Table 2) except
heart rate change. ANOVAs revealed that ethnicity and gender were not related to measures of
child distress. Child self-report ratings of injection pain were excluded if the child reported a preinjection rating of 4 or higher (on a scale of 1-10). Ten child post-injection ratings were excluded
for this reason.
Means and standard deviations for all pain scores by condition are presented in Table 3.
An Analysis of Variance (ANCOVA) was used to examine the main effect of treatment
condition, while controlling for the child’s age and also tested for a potential interaction between
treatment condition and child age. Child age continued to predict child pain and anxiety on each
dependent variable, except the physiological measure of change in child heart rate; however,
treatment condition was not significant for any of the dependent variables, nor were there any
significant interactions (Table 4).
A 3 (phase) x 3 (group) repeated measures ACNOVA was used to examine observational
distress while controlling for child age and example potential interactions. A similar pattern
emerged, with a significant main effect for child age. Additionally, there was a significant main
effect for observational distress during the 3 phases of the procedure. The LSD post-hoc test
indicating that the injection phase distress was higher than both pre- and post-injection. Further,
children had significantly more observational distress during the post-injection than the pre-

injection phase irrespective of condition. There was no main effect of treatment conditions for
observational distress, for the phase x condition interaction, or phase x condition x child age
interaction (Table 4).
DISCUSSION
Effectiveness of ShotBlocker®
This study evaluated the ShotBlocker®, a physical intervention designed to decrease
injection pain in children. The hypotheses of the current study were not supported in that the
results revealed no significant differences treatment effects in child distress on self-report,
parent-report, nurse-report, heart-rate change, or observational scale indices. Significant phase
differences suggest that the behavioral coding was sensitive to pediatric distress.
The Gate Control Theory of Pain suggests that the ShotBlocker® should interfere with
the ascending pain signal; however, results did not support the hypothesis. It could be that this
particular physical intervention did not stimulate the nerves as intended and thus was not
sufficiently effective to reduce children’s immunization pain. In could also be that this physical
intervention does provide a competing ascending signal to the brain, but that the descending
cognitive/emotional factors, such as negative expectations or pre-procedural anxiety, override
any interference caused by the physical intervention. In fact, the descending cognitive/emotional
factors may have been influenced by discussing the ShotBlocker® device, which might have
focused children’s attention to the upcoming injection.
Another explanation for the lack of effects is that the nurses or parents might have
become overly reliant on the supposed benefits of the ShotBlocker® and foregone distraction or
other coaching, which have been shown to be beneficial.21 In fact, there are data showing that
nurses provide less distraction when a topical anesthetic is used for pediatric pain relief.22

Previous research evaluating the ShotBlocker® is limited and mixed regarding the
effectiveness of the device in reducing children’s immunization pain.5,6,8.9 Given that the prior
studies were not published in peer-reviewed journals and they contain little information about
methodology, it is difficult to reconcile any differences. At this point, it is clear that there are not
sufficient data to support spending time, money, and energy on the ShotBlocker®. It is important
to disseminate information of this sort lest well-intentioned nurses waste resources on an
intervention that is not validated and forgo other methods that have considerable support (e.g.,
distraction).1,23
Limitations and Future Directions
There are several caveats to consider when interpreting the results. The sample was
homogenous in terms of class and race, with a primarily White sample and more than half the
sample reporting a family income greater than $90,000 annually. Although a homogeneous
sample increases internal validity, it raises questions regarding the generalizability of these
findings to children of different ethnicities and lower social economical classes. This is
especially pertinent given discrepancies in these findings and those with a sample from the
Philippines.5
Another limitation of the study was the wide age range of the sample, 4 to 12 years of
age, because there is a great deal of variability in prior immunization experiences in children of
different ages, which likely impacts their level of distress. However, analyses suggested age was
randomized successfully across treatment conditions. It is possible that the ShotBlocker® might
be more effective for children who can understand the purpose of the device more easily, thus
reducing their level of anxiety or other cognitive factors that could influence pain perception.
Although findings from the current study did not indicate that there is an age interaction, future

researchers should consider comparing effectiveness of the ShotBlocker® within circumscribed
age groups.
Another limitation for the study was that both intramuscular and subcutaneous injections
were included. Although this factor was randomized across conditions, there remains the
possibility that the ShotBlocker® is more effective for one needle injection and not another.
Additional research of the ShotBlocker® could answer this question. The potential influence of
the nurse script, used in the ShotBlocker® and Placebo conditions, is another important
consideration. The script was provided to increase internal validity; however, it might have
inadvertently heightened child’s focus on the injection.
The setting for the study, a group practice pediatric office, had its advantages and
disadvantages. For example, given that this was a busy pediatric practice, the staff might have
hurried through the explanation of the device to the participants, which may have minimized
potential placebo effect. On the other hand, the medical setting provided a realistic evaluation of
the effectiveness of the ShotBlocker® in a real-life setting.
Conclusions
The current study did not support the ShotBlocker® as an effective intervention to reduce
children’s pain during immunization injections. Despite the lack of significant findings, the
current study contributes to the literature on physical interventions for pediatric pain. The current
study provided additional evidence that younger children experience high injection distress and
might be in greater need for pain reduction interventions. As immunization injections are a
common procedure for children and the distress children experience has both short- and longterm consequences, it is important for researchers to continue evaluating and advocating for the
implementation of effective pain management interventions. On balance, it is also important that

research reveal when interventions are not effective lest practitioners spend time, money, and
energy on interventions that do not provide benefit to the patient.

TABLE 1. Continuous and Categorical Demographic Variables of Entire Sample and by
Condition

Entire
Sample
(n = 89)
Child Age (M, SD)
Number of Injections
Child Gender (% Male)
Child Race (% White)
NICU (% No)
Medical Condition (% No)

8.46 (2.97)
1.83 (1.05)
58.4
85.4
97.7
98.8

Note: No significant group differences.

Treatment Condition
Control
Placebo
ShotBlocker®
(n = 31)
(n = 29)
(n = 29)

8.33 (3.21)
1.84 (1.00)
61.3
93.5
96.8
100

8.24 (2.88)
1.71 (0.98)
51.7
79.3
100
96.3

8.80 (2.86)
1.93 (1.18)
62.1
82.8
96.6
100

F (df) or X2
(df)

0.30 (2, 86)
0.30 (2, 86)
0.80 (2)
11.61 (8)
0.96 (2)
2.17 (2)

TABLE 2. Bivariate correlations of Child Age with Dependent Variables
Child Age
Child Pain
Self-report
Parent-report
Nurse-report
Observational Distress Composite (Pre-Injection)
Observational Distress Composite (Injection)
Observational Distress Composite (Post-Injection)
Heart-Rate Change
Child Anxiety
Parent-report
Nurse-report
** p<.01

-.59**
-.53**
-.47**
-.36**
-.61**
-.62**
-.04
-.41**
-.39**

TABLE 3. Means and Standard Deviations of Dependent Variables by Condition

Child Pain
Self-report (FPS-R)
Parent-report (VAS)
Nurse-report (VAS)
Observational Distress Composite
(Pre-Injection)
Observational Distress Composite
(Injection)
Observational Distress Composite
(Post-Injection)
Heart-Rate Change
Child Anxiety
Parent-report (VAS)
Nurse-report (VAS)

Treatment Condition
Placebo
ShotBlocker®
(n = 29)
(n = 29)

Entire Sample
(n = 89)

Control
(n = 31)

4.31 (3.79)
37.37 (31.27)
36.25 (27.12)
.09 (.22)

4.67 (3.68)
37.81 (33.21)
36.03 (26.34)
.08 (.18)

4.00 (4.20)
37.44 (34.53)
34.39 (26.94)
.05 (.20)

4.25 (3.55)
36.83 (26.73)
38.28 (28.89)
.14 (.26)

.29 (.42)

.22 (.39)

.26 (.38)

.41 (.46)

.23 (.36)

.20 (.38)

.20 (.33)

.27 (.37)

1.91 (23.25)

3.14 (17.50)

6.33 (17.92)

-4.78 (32.63)

57.15 (36.81)
51.24 (34.07)

54.29 (37.90)
50.84 (33.63)

57.75 (37.40)
54.93 (29.24)

59.62 (36.16)
48.10 (39.31)

Note: No significant group differences.

TABLE 4. ANCOVA Analyses for Treatment Effects with Age as Covariate and Age x
Condition Interaction
F

Partial eta2

Child Age
Condition
Age x Condition
Child Age
Condition
Age x Condition
Child Age
Condition
Age x Condition
Child Age
Condition
Age x Condition

39.41**
.32
.42
36.24**
1.78
2.21
24.87**
.64
.37
.21
1.08
1.50

.36
.01
.01
.31
.04
.05
.23
.02
.01
.00
.03
.04

Child Age
Condition
Age x Condition
Child Age
Condition
Age x Condition
Child Age

17.92**
.26
.12
14.85**
.58
.86
61.16**

.18
.01
.00
.15
.01
.02
.44

Condition
Observational Distress
Observational Distress x
Condition
Observational Distress x
Condition x Child Age

2.71
37.17**
.54

.06
.30
.01

.27

.00

Factors
Child Pain
Self-report (FPS-R)

Parent-report (VAS)

Nurse-report (VAS)

Heart-Rate Change

Child Anxiety
Parent-report (VAS)

Nurse-report (VAS)

Observational Distress
Composite

Note: **p<.01

FIGURE 1. The ShotBlocker®

FIGURE 2. CONSORT Diagram Showing the Flow of Participants through Each Stage of a
Randomized Trial

Assessed for eligibility (n = Unknown)

Enrollment

Excluded (n = unknown)
Not meeting inclusion criteria
(n = unknown)
Refused to participate (n = 12)
Other reasons (n = unknown)

Analysis

Allocation

Randomized (n = 89)

Allocated to Typical Care
Control (n = 31)

Allocated to Placebo
Intervention (n = 29)

Allocated to ShotBlocker®
Intervention (n = 29)

Received allocated
intervention (n = 31)

Received allocated
intervention (n = 29)

Received allocated
intervention (n = 29)

Did not receive allocated
intervention (n = 0)

Did not receive allocated
intervention (n = 0)

Did not receive allocated
intervention (n = 0)

Analyzed (n= 31)

Analyzed (n= 29)

Analyzed (n= 29)

Excluded from analysis
(n= 3 for child
self-reported pain only)

Excluded from analysis
(n= 2 for child
self-reported pain only)

Excluded from analysis
(n= 5 for child
self-reported pain only)
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